 Up to 40 subjects will be recruited. The study is divided into two phases. For the first phase Phase I subjects are admitted to the UPenn Translational Research Center and receive two alcohol challenge sessions after pretreatment with naltrexone or placebo. Phase II continues with 12 weeks of outpatient treatment, immediately following the sessions, after random assignment to naltrexone or placebo. 